Jasper Therapeutics announced the pricing of its underwritten public offering of 60,000,000 shares of its common stock. Each share of common stock will be sold at a public offering price of $1.50 per share, for gross proceeds of approximately $90 million, before deducting underwriting discounts and commissions and offering expenses. Jasper intends to use the net proceeds from the offering for general corporate purposes, which may include capital expenditures, working capital and general and administrative expenses. In addition, Jasper has granted the underwriters a 30-day option to purchase up to 9,000,000 additional shares of its common stock, at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Jasper. The offering is expected to close on or about January 27, 2023, subject to the satisfaction of customary closing conditions. Credit Suisse Securities and William Blair & Company, L.L.C. are acting as the active book-running managers for the proposed offering. Oppenheimer & Co. Inc. is acting as a passive book-running manager for the proposed offering.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on JSPR:
- Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock
- Jasper Therapeutics Announces Proposed Public Offering of Common Stock
- Jasper Therapeutics announces common stock offering, no amount given
- Largest borrow rate increases among liquid names
- JSPR Blasts Up on New Cancer Treatment Results